NDAINJECTIONINJECTABLE
Approved
Jun 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
CAVERJECT IMPULSE (alprostadil) by Pfizer is prostaglandin receptor agonists [moa]. First approved in 2002.
Drug data last refreshed 10h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Caverject Impulse is an alprostadil injection indicated for erectile dysfunction, delivering a prostaglandin analog that acts as a vasodilator to increase penile blood flow. It is administered via intracavernosal injection and represents a small-molecule, non-oral alternative for patients who fail or cannot tolerate oral phosphodiesterase-5 inhibitors.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30), signaling potential contraction in brand team headcount and shift toward managed markets and specialty pharmacy roles.
Mechanism of Action
Prostaglandin Receptor Agonists
Pharmacologic Class:
Prostaglandin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Alprostadil in Maculopathy Study (AIMS)
Started Jul 2006
37 enrolled
Macular Degeneration
Topical Alprostadil for Female Sexual Arousal Disorder
Started Sep 2004
300 enrolled
Sexual Dysfunction, Physiological
Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV
Started Mar 2004
840 enrolled
Peripheral Arterial Occlusive Disease
Career Relevance
Working on Caverject Impulse in its LOE-approaching phase offers limited career trajectory expansion; roles are predominantly defensive and focused on maintaining share against generics and managing transition to specialty channels. Career growth opportunities are constrained, making this an ideal assignment for mid-career professionals seeking stability or transition planning rather than high-visibility launches.
Worked on CAVERJECT IMPULSE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.